Overview

Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type Psoriasis

Status:
Completed

Trial end date:
2007-05-01

Target enrollment:

Participant gender:

Summary

There is an unmet medical need for safe, effective oral therapy for moderate-to-severe psoriasis. CC-10004 will be evaluated in a controlled setting of a clinical study. The information obtained from the study will aid in the design of future clinical trials and to establish the safety and efficacy of CC-10004.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen
Celgene Corporation

Treatments:

Apremilast
Thalidomide